ABS-169 not checked

Aerys Biosciences

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Oral capsule (drug substance in capsule, no excipients), single dose of 25, 75, 150 or 200 mg taken with about 240 mL water”In the company’s words, NCT07941557 on ClinicalTrials.gov
Tested for
Cardiac Fibrosis
Main trialPhase 1
“This is the first study of ABS-169 in people. ABS-169 is an oral investigational medicine that blocks MD2-TLR4 signalling, a pathway involved in inflammation and scarring (fibrosis) of organs such as the heart. The study will test single doses of ABS-169 or placebo in healthy adult volunteers to find out how safe and well tolerated it is, how much of the medicine gets into the blood and how quickly it is removed, and whether taking it with a high-fat meal changes how it is absorbed. Up to 40 healthy adults aged 18 to 55 will take part at one study centre in Melbourne, Australia.”In the company’s words, NCT07941557 on ClinicalTrials.gov

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 1 Aug 2027 First-in-Human Study of ABS-169 in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ABS-169

Following is part of Solo: you see every change to ABS-169 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in